Drug Topics

JUNE 6, 2024

Four poster presented at ENDO 2024 examined the current landscape of diabetes.

293

293

Pharmacy Times

JUNE 6, 2024

Over the course of 15 years, epigenetic and transcriptional analysis of postmortem brain samples have revealed underlying molecular differences.

156

156

Drug Topics

JUNE 6, 2024

HbA1c levels decreased significantly after an average of 154 days in patients who used a continuous glucose monitor.

247

247

STAT

JUNE 6, 2024

The Covid pandemic has been called a “mass-disabling event” since early on — the kind of once-in-a-generation public health crisis that could shape millions of people’s lives forever. But while more people self-identified as disabled since the pandemic began, applications for disability benefits have stayed level, according to data from the Social Security Administration.

145

145

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

JUNE 6, 2024

Test your knowledge different headache types.

190

190

STAT

JUNE 6, 2024

The Patient Protection and Affordable Care Act , (generally known as the ACA), was signed into law in 2010. It expanded access to affordable, quality health care, and today is helping 45 million people — the highest total on record — be covered by health insurance. The law included long-overdue policy changes to ensure that Americans have access to recommended preventive care, which is critical to avoiding preventable illnesses and the health care spending associated with them.

Vaccines 145

Vaccines Insurance 145

STAT

JUNE 6, 2024

Federal officials, medical organizations, and reproductive health advocacy groups have expressed outrage in response to STAT’s recent investigation revealing that women with sickle cell disease have felt pressured into sterilizations as recently as 2017 and 2022. Some said they knew of other contemporary instances of tubal ligations with questionable consent — in people with severe disabilities, for instance, or situations in which patients didn’t understand that the procedu

143

143

PharmaVoice

JUNE 6, 2024

Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.

130

130

STAT

JUNE 6, 2024

No one knows when the next pandemic will sweep across the United States. It could be bird flu , or an as-yet unknown infection. But after living through the Covid-19 pandemic, which claimed more than 1 million American lives, left more than 300,000 children orphaned, and shut down workplaces and schools, U.S. citizens should demand that the nation does better next time.

141

141

Fierce Healthcare

JUNE 6, 2024

Restrictive health plan policies are increasingly relying on step therapy for cancer drugs, recent analysis from consulting firm Avalere shows. | Step therapy is embedded within prior auth requirements by health plans, potentially delaying critical access to care for cancer patients. In rare circumstances, patients must go through triple or quadruple step therapy.

122

122

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JUNE 6, 2024

A day after a panel of advisers to the Food and Drug Administration expressed deep concerns about the use of MDMA to help treat post-traumatic stress disorder, companies working to develop other psychedelics said their optimism had not been dimmed — and that the concerns provided a clearer blueprint for what it might take to get such a drug approved.

FDA 139

FDA 139

pharmaphorum

JUNE 6, 2024

Riding high from positive clinical trial results for its oral weight-loss therapy, Structure Therapeutics has filed a public offering that it hopes will raise $476 million

118

118

STAT

JUNE 6, 2024

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group. A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.

136

136

Fierce Pharma

JUNE 6, 2024

When the FDA comes knocking at your drug manufacturing facility, it’s best to play along. | In an eight-observation Form 483, the FDA chided Hengrui for a laundry list of manufacturing missteps, including poor contamination controls, subpar cleaning protocols, failure to promptly hand over documentation to inspectors and quality control shortfalls.

FDA 117

FDA Documentation 117

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

JUNE 6, 2024

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.  Sign up to get it  delivered in your inbox every Tuesday and Thursday. A new  report  from the  Peterson Health Technology Institute  suggests virtual physical therapy services could decrease health care spending for payers that invest in them.

Insurance 122

Insurance 122

Fierce Healthcare

JUNE 6, 2024

Insurers are likely to pay $1.1 billion in Affordable Care Act medical loss ratio rebates in 2024, according to a new analysis. | Insurers are likely to pay $1.1 billion in Affordable Care Act medical loss ratio rebates in 2024, according to a new analysis.

Insurance 114

Insurance 114

STAT

JUNE 6, 2024

CVS Health viewed Amy Bricker as a potential CEO. But she won’t be going to the health care conglomerate anytime soon. A federal appeals court has ruled Bricker, a former high-ranking executive at Cigna, cannot jump to CVS because it would violate her noncompete agreement that she signed while at Cigna. The appeals court’s decision backs up what a district court had previously ruled.

Insurance 117

Insurance 117

pharmaphorum

JUNE 6, 2024

CDC recommends doxyPEP as first post-exposure antibiotic for STIs including syphilis, gonorrhoea and chlamydia

111

111

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

The Checkup by Singlecare

JUNE 6, 2024

Prednisone is a corticosteroid medication that helps reduce inflammation. This versatile prescription drug is FDA-approved to treat autoimmune and inflammatory conditions such as arthritis, lupus, psoriasis, ulcerative colitis, multiple sclerosis, and endocrine disorders. It can also treat severe allergic reactions. Like any medication, prednisone may cause side effects for some people.

Dosage 111

Dosage FDA 111

pharmaphorum

JUNE 6, 2024

Trio of radiopharma financings this week, as Telix files $200m US IPO, ITM raises $202m in a private round, and AstraZeneca invests in CDMO Nucleus.

111

111

Fierce Pharma

JUNE 6, 2024

A new antitrust investigation in Italy has ensnared Novartis, Genentech, Biogen and Samsung Bioepis for allegedly colluding to suppress competition of a Lucentis biosimilar in the country. | Italy's antitrust agency is going after Novartis, Genentech, Biogen and Samsung Bioepis for allegedly working together to delay the launch of a Lucentis biosimilar in Italy.

109

109

pharmaphorum

JUNE 6, 2024

Amgen's Uplizna could become the first FDA-approved treatment for rare disease IgG4-RD, after showing efficacy in the phase 3 MITIGATE trial

FDA 111

FDA 111

STAT

JUNE 6, 2024

How did advisers react to the first psychedelic therapy to go before the Food and Drug Administration? And did the American Society of Clinical Oncology meeting surpass expectations? We discuss that and more in this week’s episode of “The Readout LOUD.” STAT colleague Meghana Keshavan joins us to dissect Lykos Therapeutics’ meeting with an FDA advisory committee.

FDA 108

FDA 108

Pharmacy Times

JUNE 6, 2024

FKS518 (Fresenius Kabi) would be indicated for the treatment of osteoporosis in men and women, including glucocorticoid-induced osteoporosis and bone loss due to prostate or breast cancer.

FDA 107

FDA 107

Pharmaceutical Technology

JUNE 6, 2024

While the potential for using AI to develop mRNA therapeutics is now a real possibility, accurate and diverse data is needed to make it a reality.

106

106

Pharmaceutical Commerce

JUNE 6, 2024

The latest news for pharma industry insiders.

105

105

STAT

JUNE 6, 2024

Top of the morning to you, and a fine one it is, despite the gray skies hovering over the Pharmalot campus again. We are doing our best to maintain sunny spirits, though, because we recall a bit of insight from the Morning Mayor, who taught us that “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and inviting you to join us.

FDA 104

FDA 104

Pharmacy Times

JUNE 6, 2024

Mirikizumab met both co-primary end points and all secondary end points at week 52, according to results presented at Digestive Disease Week in Washington DC.

101

101

Pharmaceutical Technology

JUNE 6, 2024

ArriVent BioPharma has entered a partnership with Jiangsu Alphamab Biopharmaceuticals for developing new ADCs to treat cancer.

98

98

Pharmacy Times

JUNE 6, 2024

Expert discusses the challenges faced by pharmacists in palliative and hospice care.

101

101

Pharmaceutical Technology

JUNE 6, 2024

I-Mab has agreed with Bristol Myers Squibb (BMS) to assess the givastomig regimen for advanced gastric and oesophageal cancers.

98

98

Fierce Pharma

JUNE 6, 2024

Amid a nuclear medicine boom, France’s Orano Med has chosen the U.S. to establish a manufacturing plant as it progresses on its radiopharma journey. | Orano Med—which is working on targeted alpha therapies for cancer—on Thursday inaugurated its first Alpha Therapy Laboratory (ATLab) in Brownsburg near Indianapolis, Indiana. The site marks the world’s first industrial-scale facility dedicated to production of lead-212-based radioligand therapies, the company said.

98

98

European Pharmaceutical Review

JUNE 6, 2024

Final Phase IIb data has confirmed the potential of bulevirtide 10mg in combination with pegylated interferon alfa-2a (PegIFN) as a finite therapy for adults with chronic hepatitis delta virus (HDV), according to Gilead Sciences. The new data is from the MYR204 study which investigated the efficacy and safety of the first-in-class entry inhibitor bulevirtide alone and together with PegIFN, in these patients with compensated chronic HDV infection.

98

98